Weight Management Protocol

Overview

The development of GLP-1 (glucagon-like peptide-1) receptor agonists represents one of the most significant advances in weight management pharmacology in decades. Originally developed for type 2 diabetes management, these incretin-based peptides have demonstrated substantial effects on body weight through multiple mechanisms: appetite suppression via hypothalamic signaling, delayed gastric emptying, improved insulin sensitivity, and emerging evidence of direct effects on reward-related eating behavior.

This protocol covers three GLP-1-based compounds that represent successive generations of incretin-based weight management agents. Semaglutide, the GLP-1 receptor agonist that brought widespread attention to this class. Tirzepatide, a dual GIP/GLP-1 receptor agonist that has demonstrated greater weight loss in clinical trials. And Retatrutide, a triple agonist targeting GIP, GLP-1, and glucagon receptors, currently in late-stage clinical development with the most pronounced weight loss observed to date.

Compounds Involved

Protocol Structure

All three compounds share a common structural principle: slow, mandatory dose titration over weeks to months. This is not optional — it is essential for tolerability.

Semaglutide Titration Schedule

Administration: Once weekly, subcutaneous injection, same day each week. Injection site rotation (abdomen, thigh, upper arm). No fasting requirement.

Tirzepatide Titration Schedule

Administration: Once weekly, subcutaneous injection. Same day each week.

Retatrutide Titration Schedule (Based on Clinical Trial Data)

Administration: Once weekly, subcutaneous injection. Note: Retatrutide is still in clinical trials as of 2026 and is not yet commercially approved.

Comparative Efficacy

Clinical trial data has shown progressive improvement in weight loss outcomes across generations of these compounds:

These figures represent average results from clinical trial populations with specific inclusion criteria and structured lifestyle interventions. Individual results vary significantly.

Managing Side Effects

The most common side effects of GLP-1-based compounds are gastrointestinal:

Common Side Effects

• Nausea: Most prevalent, especially during dose escalation. Typically peaks 1–3 days after each dose increase and attenuates over 2–4 weeks
• Constipation: Due to delayed gastric emptying. Adequate fiber, hydration, and in some cases osmotic laxatives may be needed
• Diarrhea: Less common than constipation but occurs in some individuals
• Decreased appetite: Intended effect, but can lead to inadequate nutrition if not managed
• Injection site reactions: Mild redness or swelling at the injection site, typically transient

Mitigation Strategies

• Eat smaller, more frequent meals: Large meals are poorly tolerated due to delayed gastric emptying
• Avoid high-fat and greasy foods: These exacerbate nausea in many individuals
• Stay hydrated: Reduced thirst sensation can lead to dehydration
• Prioritize protein: Adequate protein intake (1.2–1.6 g/kg/day minimum) is critical to preserve lean mass during weight loss
• Slow the titration: If side effects are intolerable, remain at the current dose for an additional 4 weeks before escalating
• Timing: Some individuals report fewer side effects when injecting in the evening

Serious Side Effects to Monitor

• Pancreatitis: Severe, persistent abdominal pain radiating to the back requires immediate medical attention
• Gallbladder disease: Rapid weight loss increases gallstone risk. Report right upper quadrant pain
• Thyroid concerns: GLP-1 agonists carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Report any neck mass or difficulty swallowing

Muscle Preservation During Weight Loss

A critical concern with any significant weight loss is the loss of lean body mass alongside fat. Research consistently shows that 20–40% of weight lost through caloric restriction alone is lean mass. Strategies to minimize lean mass loss include:

• Resistance training: 2–4 sessions per week of progressive resistance training is the single most effective intervention for preserving muscle during weight loss
• Protein intake: Aim for 1.2–1.6 g/kg of body weight per day at minimum, with some researchers suggesting higher targets during active weight loss
• Rate of weight loss: More gradual weight loss tends to preserve more lean mass. The rapid weight loss achievable with GLP-1 agonists makes proactive muscle preservation strategies even more important
• Creatine supplementation: 3–5 g daily may support lean mass retention during caloric deficit
• Consider GH secretagogues: Some practitioners combine GLP-1 agonists with growth hormone secretagogues to support lean mass. See the GH Secretagogue Protocol for details

Important Considerations

• Weight regain is common after discontinuation: Clinical trial data shows significant weight regain after stopping GLP-1 agonists. Long-term or indefinite use may be necessary to maintain weight loss, which underscores the importance of concurrent lifestyle modification.
• Not for cosmetic weight loss: These compounds are studied and approved for individuals with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related comorbidity.
• Drug interactions: GLP-1 agonists delay gastric emptying, which can affect the absorption of other oral medications. Oral contraceptives, antibiotics, and other time-sensitive medications may require timing adjustments.
• Contraindications: Personal or family history of medullary thyroid carcinoma or MEN2 syndrome. History of pancreatitis warrants caution.
• Compounding pharmacy considerations: Due to supply shortages, semaglutide and tirzepatide have been available through compounding pharmacies. See Compounding Pharmacy Peptides for regulatory context.
• Lab monitoring: Fasting glucose, HbA1c, lipid panel, liver enzymes, and renal function at baseline and periodically during treatment.
• Mental health: Changes in appetite, body image, and the relationship with food can have psychological effects. Some individuals report mood changes on GLP-1 agonists.

Disclaimer

This article is for educational and informational purposes only. It does not constitute medical advice, and no therapeutic claims are made. Peptide research is ongoing, and individual outcomes may vary. Consult a qualified healthcare professional before beginning any peptide protocol. All compounds discussed are intended for research purposes.